Fase IIa trial m.3243A>G mutation carriers: MABS06
In august, a phase IIa intra-subject controlled study starts at Maastricht UMC to assess the effect of three administrations of healthy autologous myogenic stem cells in adult m.3243A>G mutation carriers. Myogenic stem cells can induce myogenesis by forming new muscle fibers and by fusingwith existing muscle fibers, and autologous myogenic stem cells with a low m.3243A>G mutation load can be obtained from half of the m.3243A>G mutation carriers. Recruitment is ongoing. For more information, please contact us via email@example.com.